Featured tickers: $AEGR $AGIO $AMGN $ARNA $ARWR $BLUE $BMY $CELG $CRIS $CYNAF $DRRX $ENTA $JAZZ $PBYI $PCYC $PFE $POZN $PTIE $RCPT $REGN $RNA $RTRX $SNY $SRPT $TGTX $ZGNX
$SRPT is the most tiring and frustrating stock of my career
— Dan Rosenblum (@sharkbiotech) October 27, 2014
@adamfeuerstein Story stocks are always dangerous.
— Roy Friedman (@DewDiligence) October 27, 2014
I get the sense there are definite ulterior motives in play with respect to $PFE walking away from REMOXY. I explain in my blog. $DRRX $PTIE
— Jason Napodano, CFA (@JNapodano) October 27, 2014
#biotech getting crushed $ptie $drrx $sprt $vnda $jazz
— Dr. Tro Kalayjian (@TroKalayjianCRG) October 27, 2014
Compare stock performance of biotech mgmt that keeps promises ($TGTX, $BLUE, $ENTA) vs. mgmt that does not ($CRIS, $SRPT, $RTRX, $ARWR).
— Codes and Ciphers (@CodesandCiphers) October 27, 2014
Prediction 4 $AMGN 3Q call tonight: "Are U going to split up?" "Have you thought about splitting up?" "Do you see any value in splitting up?
— Mandy Jackson (@ScripMandy) October 27, 2014
$SRPTA's pain is $RNA's gain. Prosensa +6.3%- has its own Duchenne muscular dystrophy drug, CEO & @megtirrell joins @CNBCFastMoney 5p!
— Melissa Lee (@MelissaLeeCNBC) October 27, 2014
Being a patient, even briefly & for a relatively minor matter, makes very real & personal all the things we theorize about in #digitalhealth
— David Maizenberg (@biologypartners) October 28, 2014
CS takes $RCPT PT to 125 from 75 on 'home run' data
— Vikram Khanna (@VikramKhanna_) October 28, 2014
Appears we can cross $BMY off the list of potential acquirers of $PBYI
— Adam Feuerstein (@adamfeuerstein) October 28, 2014
Sold a bunch of stuff on my IRA: $pcyc $celg $cynaf Avg ~14% gain. Very pleased. Hoping to rebuy at lower prices.
— Joe (@Drchik23) October 28, 2014
$AMGN reit confidence in $ONXX deal, stressing upside from palbo and nexavar...or, when the icing on the cake becomes the cake
— zach (@zbiotech) October 28, 2014
Special: GoogleDoodle is Dr Jonas Salk, Polio Vaccine, devo'd at Pitt. My Uncle died of polio, my son is his namesake http://t.co/DDLk2nDYhE
— Emory Redd (@Emory_R) October 28, 2014
Plenty of spectacular blowups in biotech... they're just not so photogenic @michael_gilman
— Brian Gallagher, Jr. (@bmgallagherjr) October 29, 2014
Presumably Viebacher's fatal flaw was viewing $SNY as global pharma co, rather than French employment service... @matthewherper
— David Shaywitz (@DShaywitz) October 29, 2014
I may be a minority in thinking this, but frankly $SNY have been a disaster under Viehlbscher, especially in oncology
— Sally Church (@MaverickNY) October 29, 2014
The turmoil at Sanofi is bad for $REGN, which is coupled with $SNY for developing most of its pipeline.
— Matthew Herper (@matthewherper) October 29, 2014
I guess we should stop being surprised by the many creative ways pharma companies can shoot themselves in the foot.
— Michael Gilman (@michael_gilman) October 29, 2014
let me guess...the $ARNA bel/phen efficacy data are so unbelievable they don't wanna jeopardize presentation at the obesity society
— zach (@zbiotech) October 29, 2014
.@MikeNGladstone @ASCOPost We ask the wrong questions b/c we have limited information. Need rational #IO therapy, esp w/combos, new targets
— Paul D. Rennert (@PDRennert) October 29, 2014
.@michael_gilman @matthewherper $AMGN fires 2500, stock goes up. $SNY fires one, stock tanks. What a world.
— Martin Eglitis (@MartinEglitis) October 29, 2014
Is there a #biotech stock filter? // RT @mashable: App aims to tell friends about Twitter users at risk of suicide http://t.co/avx05D9Xcp
— LifeSciencesMkt (@LifeSciencesMkt) October 29, 2014
@getbillasap there should be an automatic disclaimer underneath all biotech tweets that reads "your guess is as good as mine"
— Pawcio (@pawcio2009) October 29, 2014
@Festo50 $POZN just needs a breather before $50
— DeadCatBill (@getbillasap) October 29, 2014
$AGIO $RCPT had all telltale sign of huge upside.... $BLUE similar stock..waiting for trigger to go higher...
— The Saint (@SimanTemplar) October 29, 2014
@pennystocksusa If it's not up 1-2% short it
— DeadCatBill (@getbillasap) October 30, 2014
@traderstewie I think every trader in my stream is watching this one. All likely using diff measures, yet all saying the same thing.
— BioBounce.com (@BioBounce) October 30, 2014
@MiltonaTrades the worst. I sold off so many CELG & PCYC calls last week. Probably cost me close to 6 figures in potential gains
— DeadCatBill (@getbillasap) October 30, 2014
@VikramKhanna_ There comes a point when it's just best to block a company from your memory, $AEGR crossed it a whole ago.
— Brad Loncar (@bradloncar) October 30, 2014
The $AEGR earnings release is an even uglier read than the divorce papers. If that is possible.
— Brad Loncar (@bradloncar) October 30, 2014
$aegr downgraded from "buy" to "bye-bye"
— Pawcio (@pawcio2009) October 31, 2014
Unfortunately I am at the highest cash levels here in a long time, didnt like yesterdays reversal raised cash, how about that sucky timing
— Dan Rosenblum (@sharkbiotech) October 31, 2014
Your results are not reproducible #ScaryStoriesIn5Words
— Alfredo Fontanini (@AF_biotech) October 31, 2014
$ZGNX Zogenix, Purdue Pharma exchange waivers of exclusivity for hydrocodone products. http://t.co/R4dJeGxObV
— Chill Till (@ChillzTrading) October 31, 2014
Sometimes the best trade is to take the small % loss before it becomes a very big one.
— Festo (@Festo50) October 31, 2014
$IBB at 300 in PM, up from intraday lows of 207 on April 15th tax day panic capitulation. Some move.
— Vikram Khanna (@VikramKhanna_) October 31, 2014
As of yesterday, the trough to peak move in the $XBI this month (intraday) is an amazing 22.8%.
— Brad Loncar (@bradloncar) October 31, 2014